ATE432716T1 - Verfahren zur behandlung von hepatozellulärem karzinom - Google Patents

Verfahren zur behandlung von hepatozellulärem karzinom

Info

Publication number
ATE432716T1
ATE432716T1 AT04777732T AT04777732T ATE432716T1 AT E432716 T1 ATE432716 T1 AT E432716T1 AT 04777732 T AT04777732 T AT 04777732T AT 04777732 T AT04777732 T AT 04777732T AT E432716 T1 ATE432716 T1 AT E432716T1
Authority
AT
Austria
Prior art keywords
zvegf3
hepatocellular carcinoma
treating hepatocellular
mammal
methods
Prior art date
Application number
AT04777732T
Other languages
German (de)
English (en)
Inventor
Thomas Palmer
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of ATE432716T1 publication Critical patent/ATE432716T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AT04777732T 2003-07-25 2004-07-09 Verfahren zur behandlung von hepatozellulärem karzinom ATE432716T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49004703P 2003-07-25 2003-07-25
PCT/US2004/021835 WO2005011742A1 (en) 2003-07-25 2004-07-09 Method of treating hepatocellular carcinoma

Publications (1)

Publication Number Publication Date
ATE432716T1 true ATE432716T1 (de) 2009-06-15

Family

ID=34115347

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04777732T ATE432716T1 (de) 2003-07-25 2004-07-09 Verfahren zur behandlung von hepatozellulärem karzinom

Country Status (9)

Country Link
US (4) US20050191304A1 (cg-RX-API-DMAC7.html)
EP (1) EP1660135B1 (cg-RX-API-DMAC7.html)
JP (1) JP4709145B2 (cg-RX-API-DMAC7.html)
AT (1) ATE432716T1 (cg-RX-API-DMAC7.html)
CA (1) CA2529798C (cg-RX-API-DMAC7.html)
DE (1) DE602004021395D1 (cg-RX-API-DMAC7.html)
DK (1) DK1660135T3 (cg-RX-API-DMAC7.html)
ES (1) ES2326978T3 (cg-RX-API-DMAC7.html)
WO (1) WO2005011742A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6893637B1 (en) * 1999-10-21 2005-05-17 Zymogenetics, Inc. Method of treating fibrosis
AU2013254690B2 (en) * 2012-04-24 2017-12-07 Thrombogenics N.V. Anti-PDGF-C antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432673B1 (en) * 1998-12-07 2002-08-13 Zymogenetics, Inc. Growth factor homolog ZVEGF3
DE69939330D1 (de) * 1998-12-07 2008-09-25 Zymogenetics Inc Wachstumsfaktor-homologe zvegf-3
US6893637B1 (en) * 1999-10-21 2005-05-17 Zymogenetics, Inc. Method of treating fibrosis

Also Published As

Publication number Publication date
JP2006528663A (ja) 2006-12-21
DE602004021395D1 (de) 2009-07-16
US20050191304A1 (en) 2005-09-01
ES2326978T3 (es) 2009-10-22
CA2529798A1 (en) 2005-02-10
DK1660135T3 (da) 2009-09-07
US20110052588A1 (en) 2011-03-03
JP4709145B2 (ja) 2011-06-22
WO2005011742A1 (en) 2005-02-10
EP1660135A1 (en) 2006-05-31
CA2529798C (en) 2014-09-16
US20090028865A1 (en) 2009-01-29
US20070054858A1 (en) 2007-03-08
EP1660135B1 (en) 2009-06-03

Similar Documents

Publication Publication Date Title
DK1638586T3 (da) Synergistisk sammensætning til behandling af diabetes mellitus
BRPI0510170B8 (pt) composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto
ATE314062T1 (de) Zusammensetzungen zur abgabe von cortisolantagonisten
DK1135153T3 (da) Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser
DE60234183D1 (de) Verwendung von methylnaltrexon zur behandlung von immunsuppression
DE602005018043D1 (de) Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
EP1140840A4 (en) -G (V) -CARBOXYARYL SUBSTITUTED DIPHENYL UREASINE AS RAF KINASE INHIBITORS
ZA200607224B (en) Tamper resistant dosage form comprising an adsorbent and an adverse agent
DE60038290D1 (de) Opioidantagonisthaltige zusammensetzung zur erhöhung der analgetischen wirksamkeit von tramadol und verringerung von ihre nebenwirkungen
FR13C0062I1 (cg-RX-API-DMAC7.html)
BRPI0519124A2 (pt) composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço
WO2006018024A3 (en) Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists
WO2006044362A3 (en) N-sulfonylpiperidine cannabinoid receptor 1 antagonists
ATE364595T1 (de) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
ATE496892T1 (de) Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen
WO2005011590A3 (en) Compositions and methods for restoring sensitivity to treatment with her2 antagonists
DE60133887D1 (de) Adenosin a2a rezeptor-antagonisten zur behandlung und vorbeugung von leberfibrose, zirrhose und fettleber
DK1207870T3 (da) Farmaceutiske præparater, der indeholder N-palmitoylethanolamid og anvendelse deraf
WO2006065722A3 (en) Compositions and methods for pulmonary conditions
EP1553449A4 (en) ACTIVE-ENERGY-FRACTIVE RESIN COMPOSITION, ACTIVE-RESTRICTIVE-RESISTANT RESIN-FILM AND METHOD FOR PRODUCING A STRUCTURE USING THE FILM
ATE465735T1 (de) Verwendung einer kombination von morphin und mindestens einem opiatantagonisten zur behandlung von opiatabhängigkeit und zur verhinderung des nicht-oralen opiatmissbrauchs bei opiatsüchtigen
WO2003051290A3 (en) Treating b-cell mediated diseases by modulating dr6 activity
DE50108168D1 (de) Transdermales therapeutisches system zur abgabe von lerisetron
DE602004021395D1 (de) Verfahren zur behandlung von hepatozellulärem karzinom
DE60133050D1 (de) Verwendung von substanzen mit oxytocin aktivität gegen klimakterische beschwerden

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1660135

Country of ref document: EP